Braveheart Bio targets $1.2 billion valuation in US IPO | PiQ Markets
2 storiesEquities & FundsIPOs & new listings
Braveheart Bio targets $1.2 billion valuation in US IPO
window 24h
IN SHORT
Millennium Management is reportedly in talks to raise approximately $20 billion in new capital, a substantial increase from its initial target. The hedge fund plans to secure these funds in two tranches and is also seeking to replace external capital from outside managers. Meanwhile, clinical-stage biopharmaceutical company Braveheart Bio is targeting a valuation of up to $1.2 billion for its U.S. initial public offering, aiming to raise $318.8 million by offering 18.8 million shares at a price range of $15 to $17 each.
✉Newsletter
PiQ Daily
Pick your topics. Get only what matters, on your cadence.
Key Numbers
$20 billionnew capital for Millennium Management
$1.2 billionvaluation target for Braveheart Bio IPO
$318.8 millionfunds Braveheart Bio aims to raise
18.8 millionshares Braveheart Bio will offer
$15 to $17price range per share for Braveheart Bio
Who's Involved
Millennium Management
Hedge fund seeking new capital
Ajay Nagpal
President of Millennium Management
Braveheart Bio
Clinical-stage biopharmaceutical company planning U.S. IPO
Key facts
Millennium Management is in talks to raise approximately $20 billion in new capital.
The new capital target for Millennium Management is a significant increase from its initial target.
Millennium Management plans to secure the funds in two tranches.
Millennium Management is seeking deals to replace external capital from outside managers.
Ajay Nagpal is president of Millennium Management.
Braveheart Bio is targeting a valuation of up to $1.2 billion in its U.S. IPO.
Braveheart Bio aims to raise $318.8 million in its IPO.
Braveheart Bio will offer 18.8 million shares.
Braveheart Bio's shares are priced between $15 and $17 each.
Hedge fund Millennium Management is reportedly in discussions to raise a substantial $20 billion in new capital, significantly exceeding its initial fundraising goals. The firm intends to acquire these funds through two separate tranches. In addition to raising capital, Millennium Management is also pursuing agreements to replace external capital currently managed by outside firms. Ajay Nagpal, president of Millennium Management, is leading these efforts.
In a separate development, Braveheart Bio, a clinical-stage biopharmaceutical company, is preparing for its U.S. initial public offering (IPO). The company is aiming for a valuation of up to $1.2 billion. Through this IPO, Braveheart Bio intends to raise $318.8 million. This will be achieved by offering 18.8 million shares to the public, with an anticipated price range set between $15 and $17 per share.
↳ Why This Matters
Hedge fund Millennium Management is reportedly in discussions to raise a substantial $20 billion in new capital, significantly exceeding its initial fundraising goals. The firm intends to acquire these funds through two separate tranches. In addition to raising capital, Millennium Management is also pursuing agreements to replace external capital currently managed by outside firms. Ajay Nagpal, president of Millennium Management, is leading these efforts.
Frequently asked questions
Braveheart Bio develops novel therapeutics for hypertrophic cardiomyopathy (HCM) and related cardiovascular diseases.
The company's lead product is BHB-1893, an oral cardiac myosin inhibitor designed to treat HCM.
Since its inception in 2024, Braveheart Bio has raised approximately $185 million in Series A financing.
Braveheart Bio intends to list its shares on the Nasdaq Global Market.
What Happens Next
01Braveheart Bio intends to list its shares on the Nasdaq Global Market under the symbol "BRVE".
Get the newsletter.
Pick the topics you actually care about. We'll email when there's news worth your time, on the cadence you choose. Cancel any time from your account.
